Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal, Los Angeles Times, USA Today and Reason Magazine. Patrick has appeared on Crossfire and Nightline, and been written up in The Baltimore Sun and CNBC Magazine. Now, Patrick edits Breakthrough Technology Alert and Technology Profits Confidential, uncovering transformational technologies that offer exponential gains.
I'd like to tell you about a couple of important new breakthroughs that have just shown up on the radar. Both have enormous potential in terms of both your health and your portfolio.
I'm sending this out on a weekend because I to make sure you have a change to prepare before the market opens Monday morning. We need to sell Advanced Cell Technology, Inc. (OTCBB:ACTC)
Let me explain. First, of course, I have to acknowledge that the financial media are vacillating between panic and despair. The bill is finally coming due for two of the most incredibly stupid policies in modern history.
For reasons I explained in the letter, the stock went up immediately. The biggest upward influence was the information presented by Anavex scientists at the Alzheimer's Association International Conference in Chicago last week.
It's great to be writing to you again. I hope everything is well with you. It's hard to get a handle on the latest salmonella outbreak. Certainly, the FDA hasn't figured out where the toxin is coming from.
In March, I put China Direct Inc. (CDS: NASDAQ) on our buy list. Since then, it's been increasing in value nicely. The company has scored a number of successes and, at one point, doubled in price.
I've had several interesting messages from readers recently. The most gratifying came from Dr. Tom Schmidt, who runs the doctoral-level information technology program for a major university.
Another remarkable week has come and passed. You know that the pace of technological change is increasing. Even as a professional tech watcher, however, I'm surprised how fast things have been developing of late.
It's a great time to be an investor. I've got terrific news about Alnylam Pharmaceuticals (ALNY: NASDAQ). Alnylam was my first stock pick back in January, when I took on this charter.
I've just finished this month's newsletter. We are is preparing it now, so you'll have the electronic version soon. The "dead tree" version will follow shortly after.